Sarina Redmond
Payments from drug & device makers
Across 149 payments — averaging $14.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$395
- Novo Nordisk$359
- Boehringer Ingelheim$209
- Amgen$185
- Lilly USA, LLC$162
- GSK$161
- plus $682 from 18 others
What the payments were for
- Food & beverage$2,153100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 46 | $395 |
| Novo Nordisk | 27 | $359 |
| Boehringer Ingelheim | 9 | $209 |
| Amgen | 10 | $185 |
| Lilly USA, LLC | 11 | $162 |
| GSK | 9 | $161 |
| Bayer | 5 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $82 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| AstraZeneca(2 entities) | 4 | $54 |
| Novartis | 3 | $54 |
| Exact Sciences | 2 | $41 |
| Amarin Pharma, Inc. | 2 | $40 |
| Indivior Inc. | 2 | $38 |
| Abbott | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| Pfizer | 2 | $29 |
| Dexcom, Inc. | 1 | $23 |
| Vivus LLC | 1 | $20 |
| Fidia Pharma USA Inc. | 1 | $19 |
| Pulmonx Corporation | 1 | $18 |
| Intra-sana Laboratories | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $15 |
How this compares
$2,153 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 56 | $94,016 |
| JardianceEmpagliflozin | 68 | $64,828 |
| TrulicityDulaglutide | 21 | $27,593 |
| RybelsusSemaglutide | 15 | $24,743 |
| Spiriva RespimatTiotropium Bromide | 16 | $20,344 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $13,120 |
| FarxigaDapagliflozin Propanediol | 19 | $12,477 |
| MounjaroTirzepatide | 11 | $11,384 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,420 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $5,104 |
| Colesevelam Hcl | 15 | $2,865 |
| Duloxetine Hcl | 41 | $2,843 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $1,926 |
| Insulin Lispro Protamine MixInsulin Lispro Protamin/Lispro | 11 | $1,767 |
| Atorvastatin Calcium | 146 | $1,744 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $359 | $118,75971 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $209 | $85,17384 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $162 | $38,97732 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $161 | $18,54027 claims |
| AstraZenecaFarxiga | $54 | $12,47719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,657 family providers in Michigan.
Other family in Flint
- Rachael CompeauFlint$62K
- Julie WidzinskiFlint$16K
- Amy WulkeFlint$11K
- Laura SzakalFlint$10K
- Jayme HeimGrandville$663K
- Susan WolgamottBloomfield Township$327K
- Elisheva EllenbergDetroit$150K
- Sarah JohnsonFarmington Hills$119K
- Daniela MaximTroy$112K
- Kelsey PrinceGrand Rapids$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.